Key challenges in bringing CRISPR-mediated somatic cell therapy into the clinic
journal contribution
posted on 2023-05-22, 03:14 authored by Dianne NicolDianne Nicol, Lisa EcksteinLisa Eckstein, Morrison, M, Sherkow, JS, Margaret OtlowskiMargaret Otlowski, Whitton, T, Bubela, T, Kathryn BurdonKathryn Burdon, Donald ChalmersDonald Chalmers, Chan, S, Jac CharlesworthJac Charlesworth, Critchley, C, Crossley, M, de Lacey, S, Joanne DickinsonJoanne Dickinson, Alexander HewittAlexander Hewitt, Kamens, J, Kato, K, Kleiderman, E, Kodama, S, Liddicoat, J, David MackeyDavid Mackey, Newson, AJ, Jane NielsenJane Nielsen, Wagner, JK, Rebekah McWhirterRebekah McWhirterGenome editing using clustered regularly interspersed short palindromic repeats (CRISPR) and CRISPR-associated proteins offers the potential to facilitate safe and effective treatment of genetic diseases refractory to other types of intervention. Here, we identify some of the major challenges for clinicians, regulators, and human research ethics committees in the clinical translation of CRISPRmediated somatic cell therapy.
History
Publication title
Genome MedicineVolume
9Article number
85Number
85Pagination
1-4ISSN
1756-994XDepartment/School
Faculty of LawPublisher
BioMed Central Ltd.Place of publication
United KingdomRights statement
Copyright 2017 The Authors. Licensed under Creative Commons Attribution 4.0 International (CC BY 4.0) https://creativecommons.org/licenses/by/4.0/Repository Status
- Open
